Top

Published in:

01-05-2014 | Original Paper

Fibroblast-activation protein: valuable marker of cutaneous epithelial malignancy

Authors: Jinane El Khoury, Mazen Kurban, Abdul-Ghani Kibbi, Ossama Abbas

Published in: Archives of Dermatological Research | Issue 4/2014

Abstract

Fibroblast-activation protein (FAP) is a key protein that is characteristically expressed by carcinoma-associated fibroblasts (CAFs). It has been shown to be expressed in CAFs of 90 % of internal epithelial cancers as well as cutaneous epithelial malignancies. We have recently shown that this marker is useful in differentiating between morpheaform/infiltrative BCC from desmoplastic trichoepithelioma (TE). Given this, we sought to assess FAP expression in both benign and malignant cutaneous epithelial entities. Immunohistochemical FAP staining was performed on BCC (n = 26), SCC (n = 26), porocarcinoma (n = 10), metastatic adenocarcinoma (n = 12), keratoacanthoma (KA) (n = 16), TE (n = 14), pseudoepitheliomatous hyperplasia (n = 15), poroma (n = 15), syringoma (n = 10), and chondroid syringoma (n = 6). Control group consisted of scars (n = 10). FAP expression was observed in all scars and all malignant entities, but not in any of the benign cases. Interestingly, ten KA cases exhibited positivity, whereas six were negative. In summary, FAP is a reliable marker of cutaneous epithelial malignancy.

Abbas O, Richards JE, Mahalingam M (2010) Fibroblast-activation protein: a single marker that confidently differentiates morpheaform/infiltrative basal cell carcinoma from desmoplastic trichoepithelioma. Mod Pathol 23:1535–1543PubMedCrossRef

Akalin T, Sen S, Yücetürk A, Kandiloğlu G (2001) P53 protein expression in eccrine poroma and porocarcinoma. Am J Dermatopathol 23:402–406PubMedCrossRef

Altemani AM, Crespo A, Cardinalli IA, Norato D (1995) Nucleolar organizer region (NORs) in pseudocarcinomatous hyperplasia and squamous cell carcinoma of the oral mucosa. Sao Paulo Med J 113:693–697PubMedCrossRef

Ariga N, Sato E, Ohuchi N, Nagura H, Ohtani H (2001) Stromal expression of fibroblast activation protein/seprase, a cell membrane serine proteinase and gelatinase, is associated with longer survival in patients with invasive ductal carcinoma of breast. Int J Cancer 95:67–72PubMedCrossRef

Chen WTKT (2003) Seprase complexes in cellular invasiveness. Cancer Metastasis Rev 22:259–269PubMedCrossRef

Cheng JD, Dunbrack RL Jr, Valianou M, Rogatko A, Alpaugh RK, Weiner LM (2002) Promotion of tumor growth by murine fibroblast activation protein, a serine protease, in an animal model. Cancer Res 62:4767–4772PubMed

Choi CW, Park HS, Kim YK, Lee SH, Cho KH (2008) Elastic fiber staining and cytokeratin 15 expression pattern in trichoepithelioma and basal cell carcinoma. J Dermatol 35:499–502PubMedCrossRef

Cohen SJ, Alpaugh RK, Palazzo I, Meropol NJ, Rogatko A, Xu Z, Hoffman JP, Weiner LM, Cheng JD (2008) Fibroblast activation protein and its relationship to clinical outcome in pancreatic adenocarcinoma. Pancreas 37:154–158PubMedCrossRef

Dienus K, Bayat A, Gilmore BF, Seifert O (2010) Increased expression of fibroblast activation protein-alpha in keloid fibroblasts: implications for development of a novel treatment option. Arch Dermatol Res 302:725–731PubMedCrossRef

10.

Dolznig H, Schweifer N, Puri C, Kraut N, Rettig WJ, Kerjaschki D, Garin-Chesa P (2005) Characterization of cancer stroma markers: in silico analysis of an mRNA expression database for fibroblast activation protein and endosialin. Cancer Immun 5:10PubMed

11.

Edosada CY, Quan C, Wiesmann C, Tran T, Sutherlin D, Reynolds M, Elliott JM, Raab H, Fairbrother W, Wolf BB (2006) Selective inhibition of fibroblast activation protein protease based on dipeptide substrate specificity. J Biol Chem 281:7437–7444PubMedCrossRef

12.

Franco OE, Shaw AK, Strand DW, Hayward SW (2010) Cancer associated fibroblasts in cancer pathogenesis. Semin Cell Dev Biol 21:33–39PubMedCentralPubMedCrossRef

13.

Galan A, Ko CJ (2007) Langerhans cells in squamous cell carcinoma vs. pseudoepitheliomatous hyperplasia of the skin. J Cutan Pathol 34:950–952PubMedCrossRef

14.

Garin-Chesa P, Old LJ, Rettig WJ (1990) Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proc Natl Acad Sci U S A 87:7235–7239PubMedCentralPubMedCrossRef

15.

Gemer O, Piura B, Segal S, Inbar IY (2003) Adenocarcinoma arising in a chondroid syringoma of vulva. Int J Gynecol Pathol 22:398–400PubMedCrossRef

16.

Gerber PA, Schulte KW, Ruzicka T, Bruch-Gerharz D (2008) Eccrine porocarcinoma of the head: an important differential diagnosis in the elderly patient. Dermatology 216:229–233PubMedCrossRef

17.

Goodman J, Rozypal TL, Kelly T (2003) Seprase, a membrane-bound protease, alleviates the serum growth requirement of human breast cancer cells. Clin Exp Metast 20:459–470CrossRef

18.

Henry LR, Lee HO, Lee JS, Klein-Szanto A, Watts P, Ross EA, Chen WT, Cheng JD (2007) Clinical implications of fibroblast activation protein in patients with colon cancer. Clin Cancer Res 13:1736–1741PubMedCrossRef

19.

Huang Y, Simms AE, Mazur A, Wang S, León NR, Jones B, Aziz N, Kelly T (2011) Fibroblast activation protein-alpha promotes tumor growth and invasion of breast cancer cells through non-enzymatic functions. Clin Exp Metastasis 28:567–579PubMedCrossRef

20.

Huang Y, Wang S, Kelly T (2004) Seprase promotes rapid tumor growth and increased microvessel density in a mouse model of human breast cancer. Cancer Res 64:2712–2716PubMedCrossRef

21.

Huber MA, Kraut N, Park JE, Schubert RD, Rettig WJ, Peter RU, Garin-Chesa P (2003) Fibroblast activation protein: differential expression and serine protease activity in reactive stromal fibroblasts of melanocytic skin tumors. J Invest Dermatol 120:182–188PubMedCrossRef

22.

Huber MA, Kraut N, Schweifer N, Dolznig H, Peter RU, Schubert RD, Scharffetter-Kochanek K, Pehamberger H, Garin-Chesa P (2006) Expression of stromal cell markers in distinct compartments of human skin cancers. J Cutan Pathol 33:145–155PubMedCrossRef

23.

Keane FM, Nadvi NA, Yao TW, Gorrell MD (2011) Neuropeptide Y, B-type natriuretic peptide, substance P and peptide YY are novel substrates of fibroblast activation protein-alpha. FEBS J 278:1316–1332PubMedCrossRef

24.

Kerschmann RL, McCalmont TH, LeBoit PE (1994) p53 oncoprotein expression and proliferation index in keratoacanthoma and squamous cell carcinoma. Arch Dermatol 130:181–186PubMedCrossRef

25.

Klieb HB, Raphael SJ (2007) Comparative study of the expression of p53, Ki67, E-cadherin and MMP-1 in verrucous hyperplasia and verrucous carcinoma of the oral cavity. Head Neck Pathol 1:118–122PubMedCentralPubMedCrossRef

26.

Kraman M, Bambrough PJ, Arnold JN, Roberts EW, Magiera L, Jones JO, Gopinathan A, Tuveson DA, Fearon DT (2010) Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science 330:827–830PubMedCrossRef

27.

Lee HO, Mullins SR, Franco-Barraza J, Valianou M, Cukierman E, Cheng JD (2011) FAP-overexpressing fibroblasts produce an extracellular matrix that enhances invasive velocity and directionality of pancreatic cancer cells. BMC Cancer 11:245PubMedCentralPubMedCrossRef

28.

Lee YS, Teh M (1994) p53 expression in pseudoepitheliomatous hyperplasia, keratoacanthoma, and squamous cell carcinoma of skin. Cancer 73:2317–2323PubMedCrossRef

29.

Li J, Lee YS (1996) Proliferating cell nuclear antigen (PCNA) expression in pseudoepitheliomatous hyperplasia, keratoacanthoma and squamous cell carcinoma of the skin. Ann Acad Med Singapore 25:526–530PubMed

30.

Li J, Wang K, Gao F, Jensen TD, Li ST, DeAngelis PM, Kølvraa S, Proby C, Forslund O, Bolund L, Clausen OP (2012) Array comparative genomic hybridization of keratoacanthomas and squamous cell carcinomas: different patterns of genetic aberrations suggest two distinct entities. J Invest Dermatol 132:2060–2066PubMedCrossRef

31.

Mahalingam M, Nguyen LP, Richards JE, Muzikansky A, Hoang MP (2010) The diagnostic utility of immunohistochemistry in distinguishing primary skin adnexal carcinomas from metastatic adenocarcinoma to skin: an immunohistochemical reappraisal using cytokeratin 15, nestin, p63, D2-40, and calretinin. Mod Pathol 23:713–719PubMedCrossRef

32.

O’Brien P, O’Connor BF (2008) Seprase: an overview of an important matrix serine protease. Biochim Biophys Acta 1784:1130–1145PubMedCrossRef

33.

Quinn AG, Sikkink S, Rees JL (1994) Basal cell carcinomas and squamous cell carcinomas of human skin show distinct patterns of chromosome loss. Cancer Res 54:4756–4759PubMed

34.

Park JE, Lenter MC, Zimmermann RN, Garin-Chesa P, Old LJ, Rettig WJ (1999) Fibroblast activation protein, a dual specificity serine protease expressed in reactive human tumor stromal fibroblasts. J Biol Chem 274:36505–36512PubMedCrossRef

35.

Pham TT, Selim MA, Burchette JL Jr, Madden J, Turner J, Herman C (2006) CD10 expression in trichoepithelioma and basal cell carcinoma. J Cutan Pathol 33:123–128PubMedCrossRef

36.

Poniecka AW, Alexis JB (1999) An immunohistochemical study of basal cell carcinoma and trichoepithelioma. Am J Dermatopathol 21:332–336PubMedCrossRef

37.

Ramirez-Montagut T, Blachere NE, Sviderskaya EV, Bennett DC, Rettig WJ, Garin-Chesa P, Houghton AN (2004) FAPalpha, a surface peptidase expressed during wound healing, is a tumor suppressor. Oncogene 23:5435–5446PubMedCrossRef

38.

Robson A, Greene J, Ansari N, Kim B, Seed PT, McKee PH, Calonje E (2001) Eccrine porocarcinoma (malignant eccrine poroma): a clinicopathologic study of 69 cases. Am J Surg Pathol 25:710–720PubMedCrossRef

39.

Sarda R, Sankaran V, Ratnakar C, Veliath AJ, Prema V (1995) Application of the AgNOR method to distinguish pseudoepitheliomatous hyperplasia from squamous cell carcinoma. Indian J Cancer 32:169–174PubMed

40.

Wu M, Putti TC, Bhuiya TA (2002) Comparative study in the expression of p53, EGFR, TGF-alpha, and cyclin D1 in verrucous carcinoma, verrucous hyperplasia, and squamous cell carcinoma of head and neck region. Appl Immunohistochem Mol Morphol 10:351–356PubMedCrossRef

41.

Zarovnaya E, Black C (2005) Distinguishing pseudoepitheliomatous hyperplasia from squamous cell carcinoma in mucosal biopsy specimens from the head and neck. Arch Pathol Lab Med 129:1032–1036PubMed

Title: Fibroblast-activation protein: valuable marker of cutaneous epithelial malignancy
Authors: Jinane El Khoury
Mazen Kurban
Abdul-Ghani Kibbi
Ossama Abbas
Publication date: 01-05-2014
Publisher: Springer Berlin Heidelberg
Published in: Archives of Dermatological Research / Issue 4/2014
Print ISSN: 0340-3696
Electronic ISSN: 1432-069X
DOI: https://doi.org/10.1007/s00403-014-1456-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Fibroblast-activation protein: valuable marker of cutaneous epithelial malignancy

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2014

Expression of ZNF396 in basal cell carcinoma

Investigation of four novel male androgenetic alopecia susceptibility loci: no association with female pattern hair loss

Annexin A2 participates in human skin keloid formation by inhibiting fibroblast proliferation

Expression and function of NET-1 in human skin squamous cell carcinoma

miR-205 down-regulation promotes proliferation of dermatofibrosarcoma protuberans tumor cells by regulating LRP-1 and ERK phosphorylation

B-Myb enhances proliferation and suppresses differentiation of keratinocytes in three-dimensional cell culture